Viewing Study NCT07213960


Ignite Creation Date: 2025-12-25 @ 2:06 AM
Ignite Modification Date: 2025-12-26 @ 2:35 AM
Study NCT ID: NCT07213960
Status: NOT_YET_RECRUITING
Last Update Posted: 2025-10-09
First Post: 2025-09-15
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Sponsor: Apellis Pharmaceuticals, Inc.
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module